Celltrion Pharm, Inc. Overview
Celltrion Pharm is the Korean commercial and fill-finish arm of the Celltrion biosimilar group. It runs three businesses:
Chemical pharmaceuticals: A domestic prescription franchise anchored by the liver drug Godex, the hypertension drug Dilatrend, and diabetes and hypertension brands acquired from Takeda in 2020 (Nesina, Actos, Idalbi).
Biosimilars: Exclusive domestic sales of parent Celltrion's biosimilars, from legacy Remsima, Truxima and Herzuma to newer Yuflyma, Vegzelma, Steqeyma, Omlyclo, Eydenzelt, Stoboclo-Osenvelt and Avtozma.
Contract manufacturing (CMO): Mainly prefilled-syringe (PFS) fill-finish for Celltrion's subcutaneous products sold globally, including Remsima SC (US brand Zymfentra) and Yuflyma, from GMP-certified lines in Cheongju.
FY2025 revenue reached a record KRW 536.4 bn, with operating profit of KRW 56.1 bn. The company's growth and margins are increasingly driven by Celltrion-linked biosimilar distribution and CMO volumes rather than generics. That shift makes it a leveraged, but concentrated, play on its parent's subcutaneous-formulation strategy.
What the company does. Celltrion Pharm develops, manufactures and sells chemical (small-molecule) medicines in Korea. It is the exclusive Korean distributor of Celltrion, Inc.'s biosimilars. It also provides contract manufacturing services, principally aseptic filling of prefilled syringes. Third-party company descriptions (e.g., the StockHub profile derived from exchange data) list its therapeutic coverage as:
-
liver function improvers
-
anti-inflammatories and antihistamines
-
respiratory, cardiovascular and gastrointestinal drugs
-
hormone and metabolic-disease drugs
-
antibiotics and antifungals
-
nutritional and tonic products
-
immunology and oncology biologics
Customers are university and general hospitals, clinics, and community pharmacies.
Revenue model. Revenue is overwhelmingly product sales plus contract manufacturing service fees. There is no material subscription or licensing income. Based on FY2025 disclosed segment data:
Chemical products: (owned brands, in-licensed and acquired brands, generics): ~40% of revenue on the disclosed segment figure. The share is higher if undisclosed "other" revenue is chemical.
Biosimilar distribution: ~24%. Celltrion Pharm buys finished biosimilars from Celltrion and resells them in Korea. This is a distribution-margin model.
CMO / contract services: ~26%. Mostly PFS commercial production for Celltrion, plus commercial production of in-sourced products and other pharmaceutical services.
In H1 2026, biosimilar plus CMO revenue exceeded 53.8% of sales for the first time (IBK Investment & Securities initiation, September 2026). That marks the structural pivot away from generics.
Value-chain position.
Chemicals: vertically integrated. R&D of incremental modified drugs (개량신약) and combinations, API sourcing, finished-dose manufacturing at Ochang and Jincheon, and domestic sales and marketing. The company has "in-sourced" production of Takeda-origin brands (Nesina, Actos, Idalbi) that were previously imported, improving gross margin.
Biosimilars: downstream only. Domestic commercialisation (hospital drug-committee listings, tenders, medical marketing) of products developed and manufactured by Celltrion.
CMO: mid-stream. Drug product (fill-finish) manufacturing of Celltrion drug substance into prefilled syringes for global supply.
Customer types and end markets.
-
Korean tertiary and general hospitals (biosimilars, specialty chemicals)
-
Clinics and pharmacies (primary-care chemicals)
-
Celltrion, Inc. as a related-party CMO customer. IBK estimated ~88% of H1 2026 CMO revenue came from Celltrion-directed PFS production.
End markets: Korean prescription drug market (hepatology, cardiometabolic, diabetes, immunology, oncology, ophthalmology, allergy/respiratory, bone), plus global SC biologic demand indirectly via CMO.
Company's own characterisation. In its earnings releases the company describes FY2025 as a year in which top-line growth combined with cost and cost-of-goods improvements. It names three operating levers:
-
strengthening competitiveness of core products;
-
keeping PFS fill-finish lines at maximum utilisation;
-
improving chemical profitability through in-sourced brands (Nesina, Actos, Idalbi).
It frames 2026 as continued "high growth" with a profitability focus. (Paraphrased from the FY2025 preliminary results release, 5 February 2026.)
Independent characterisation. Celltrion Pharm is best understood as a captive service and distribution satellite of Celltrion, Inc., with a declining-share generics base attached. Its economics are set by three things:
-
domestic biosimilar uptake, which Korean government policy increasingly favours;
-
Celltrion's global SC-formulation volumes, which drive PFS utilisation;
-
intra-group transfer pricing on both the distribution and CMO legs.
This creates genuine growth optionality, notably the announced KRW 2 trn PFS capacity plan. It also creates material related-party concentration and governance considerations. Those considerations were central to the failed 2024 merger, when parent-company shareholders argued Celltrion Pharm's market value exceeded its fundamental value.
Strategy
Stated corporate strategy (themes paraphrased from FY2024–FY2026 earnings releases and investor communications)
-
Strengthen core-product competitiveness: Godex, Dilatrend, Remsima, Truxima.
-
Rapid market entry of new biosimilars: data-led, indication-specific academic marketing for Steqeyma, Eydenzelt, Omlyclo and later launches.
-
Maximise PFS line utilisation and expand CMO: capitalise on global SC formulation demand.
-
Chemical profitability via in-sourcing: Nesina, Actos, Idalbi.
-
Differentiated R&D: combination and incrementally modified drugs in diabetes and hypertension.
-
Profitability-centred stable growth: the 2026 guidance framing.
Strategic initiatives in the last 24 months
Sustainability and ESG commitments: not publicly disclosed specifically for Celltrion Pharm.
Cost programmes: none announced with quantified targets. Management credits commission savings and production in-sourcing for margin gains.
Medium-term financial targets and guidance
-
No explicit quantitative revenue or margin guidance for Celltrion Pharm was found in public disclosures for 2026 or beyond. The company's guidance language is "maintain high growth" with a profitability focus.
-
A "future business/management plan" fair disclosure (장래사업ㆍ경영계획) was filed by Celltrion Pharm in mid-2026 (StockHub disclosure index).
-
Parent-level context: Celltrion targets KRW 5.3 trn revenue in 2026 (an implied KRW 1.8 trn operating profit is cited by the Korea Herald). It targets 18 biosimilars by 2030, 41 by 2038, and ~20 novel-drug candidates by 2027.
Products & Services
Pricing for Korean prescription drugs is set by the national reimbursement list (HIRA/MOHW price notification). Individual product prices are not disclosed in company releases. "Latest sales" figures are company-disclosed revenues.
Chemical Pharmaceuticals
| Product | Description / mechanism | Indication / target | Origin & timing | Latest disclosed sales (KRW Bn) |
|---|---|---|---|---|
| Godex Capsules (고덱스캡슐) | Hepatoprotective "liver solvent" combination capsule. Flagship legacy Hanseo product. | Liver-function improvement (chronic liver disease, elevated liver enzymes). Hospital and clinic prescribing. | Hanseo origin; acquired with Hanseo in 2009. Survived a price re-evaluation in 2023. Chong Kun Dang's FY2024 commentary references Godex among products it introduced to its own sales line-up, indicating a domestic co-promotion arrangement (terms not disclosed). | FY2020 65.7; FY2023 69.1 (+11%); FY2024 66.8; FY2025 68.4 (+2.4%); Q2 2026 17.7 (+10.1%) |
| Dilatrend Tablets (딜라트렌정) | Carvedilol (beta/alpha-1 blocker) | Hypertension; cardiovascular | Full-scale sales by Celltrion Pharm began in 2024. | FY2024 50.2; FY2025 57.4 (+14.3%); Q2 2025 15.1 |
| Nesina family (네시나, 네시나액트, etc.) | Alogliptin (DPP-4 inhibitor) and fixed-dose combinations. Nesina Act = alogliptin + pioglitazone. | Type 2 diabetes | Takeda acquisition (2020); licence transfers completed Jan 2022. Production in-sourced. | Nesina Act ~11.2 (2021 outpatient Rx, UBIST, pre-transfer); Nesina Q2 2025 6.4 (+65.7%) |
| Actos (액토스) | Pioglitazone (TZD) | Type 2 diabetes | Takeda acquisition. In-sourced production. | Q2 2025 1.8 |
| Idalbi (이달비) | Azilsartan (ARB) | Hypertension | Takeda acquisition. Production in-sourced (completed by 2024). | FY2023 >10.0 (+14.8%); Q2 2025 2.7 |
| Amlozet Tablets (암로젯정) | Three-drug fixed combination for hypertension plus hyperlipidaemia | Patients with co-morbid hypertension and dyslipidaemia | In-house incrementally modified drug; approved and launched Feb 2025 | Grouped with Nesina/Actos in Q2 2026 commentary (~8.6 combined, +4.2%) |
| Donerion Patch (도네리온패취) | Donepezil transdermal patch, applied twice weekly (vs once-daily oral) | Alzheimer's dementia | In-house incrementally modified drug; MFDS approval ~2021–22 | — |
| Other generics portfolio | Broad domestic generic range (cardiovascular, GI, CNS, anti-infectives, etc.) built after the 2015 Ochang plant opening | Primary care and hospitals | 70+ approvals in 2015–2017 | "Other generics" revenue grew from KRW 9.3 bn (2010) to KRW 115.2 bn (2024) (IB Tomato) |
| Global chemical products | Export chemical products, including HIV antiretroviral CT-G7 | International tenders / partners | Commercial ramp from Q3 2020 | ~43 (FY2020); later years not itemised |
| Pipeline: combination modified drugs | FY2023 disclosures: development completed for 3 hypertension products, 1 herpes zoster antiviral, 1 liver product. Primary hypercholesterolaemia plus essential hypertension combination in registration (this became Amlozet). | Chronic disease | R&D focus on diabetes and hypertension combinations | — |
Biosimilars (domestic exclusive distribution of Celltrion products)
| Product | Molecule (reference) | Indication area | Korean launch / status | Latest disclosed sales (KRW Bn) and share data |
|---|---|---|---|---|
| Remsima (IV) | Infliximab (Remicade) | Autoimmune: RA, IBD, AS, psoriasis | Long-established | FY2023 40.4 (+24.9%); Q2 2026 11.5 (+19.2%). Domestic market share 39% in Q2 2024, highest in 3 years. |
| Remsima SC | Infliximab subcutaneous | IBD, RA | Domestic supply from 2021–22 (passed ~75 hospital drug committees by Feb 2022) | Sales not separately disclosed |
| Truxima | Rituximab (MabThera/Rituxan) | Blood cancers, RA | Established | FY2023 14.9; Q2 2026 4.3 (+20.7%). Domestic share >30% for first time in Q2 2024. |
| Herzuma | Trastuzumab (Herceptin) | HER2+ breast and gastric cancer | Established | FY2023 14.9 |
| Yuflyma | Adalimumab, high-concentration, citrate-free (Humira) | Autoimmune | Launched 2022 | FY2024 3.6 (+77%); Q2 2025 1.8; Q2 2026 2.4 (+28.6%) |
| Vegzelma | Bevacizumab (Avastin) | Oncology | Launched 2022 | Q2 2025 2.0; Q2 2026 4.0 (+93.9%) |
| Steqeyma | Ustekinumab (Stelara) | Psoriasis, Crohn's, UC | Launched 1 Sep 2024 | Q2 2026 0.4 |
| Omlyclo | Omalizumab (Xolair) | Allergic asthma, chronic urticaria | Launched 1 Sep 2024. Celltrion added a pen formulation globally. | Q2 2026 1.2 (+206.5%) |
| Eydenzelt | Aflibercept (Eylea) | Ophthalmology (nAMD, DME) | Launched 1 Sep 2024 | — |
| Stoboclo / Osenvelt | Denosumab (Prolia / Xgeva) | Osteoporosis / bone metastases | Launched 2025 | Included in "new products" KRW 9.7 bn (Q2 2025, with Steqeyma, Eydenzelt, Omlyclo) |
| Avtozma | Tocilizumab (Actemra) | RA, GCA, JIA | Korean approval filed Feb 2024; contributing by 2026 | Q2 2026 0.4 |
| Pipeline from parent | CT-P55 (secukinumab / Cosentyx), Herzuma SC (CT-P6 SC; Korean filing 28 May 2026), Keytruda- and Darzalex-referencing programmes | Various | Parent targets 18 biosimilars by 2030 and 41 by 2038. Note: CT-P51 (pembrolizumab) European Phase 3 was terminated early and the trial application voluntarily withdrawn (2026 disclosure). | — |
Contract Manufacturing (CMO / 위수탁생산)
| Service | Description | Customer | Status | Latest disclosed revenue (KRW Bn) |
|---|---|---|---|---|
| PFS commercial production | Aseptic fill-finish of biologics into prefilled syringes. Supports Celltrion SC products: Remsima SC / Zymfentra, Yuflyma, plus SC demand across Herzuma and Truxima referenced in FY2025 commentary. | Celltrion, Inc. (~88% of H1 2026 CMO revenue per IBK) | GMP: MFDS, EMA, ANVISA, US FDA, PMDA. Lines at maximum utilisation through 2025. Current capacity ~20 m syringes/year. | FY2024 92.6 (+265%); Q2 2026 35.3 (+51.9%) |
| Commercial production of in-sourced products | Manufacturing of formerly imported brands (Takeda-origin) | Internal / group | Ongoing | Included in CMO total |
| Other pharmaceutical services (제약용역) | Ancillary services | Group / third parties | Ongoing | Included in CMO total |
| Planned PFS expansion | +50 m syringes/year (to 70 m total). Phase 1 ~KRW 1 trn; total programme ~KRW 2 trn. | Celltrion global SC demand; external CMO ambitions | Announced 2 Jul 2026. Design and groundbreaking 2028; operation 2032. Site under review (Ochang/Osong/Jincheon cited in different reports). | — |
Financial Narrative
Basis: K-IFRS separate. All figures KRW bn unless stated.
Sources by year:
-
FY2021: preliminary results, 23 Feb 2022 (Medigate/Biospectator)
-
FY2022: derived from the FY2023 release's stated YoY changes (Dealsite, 18 Mar 2024): revenue +0.7% (+KRW 2.8 bn), operating profit −5.5% (−KRW 2.1 bn), net income −18.1% (−KRW 4.7 bn)
-
FY2023: Dealsite/Biospectator, 18 Mar 2024
-
FY2024: Dealsite/Bizwatch, 17 Mar 2025
-
FY2025: Dealsite/Medifonews, 5 Feb 2026
-
Balance sheets and cash flows: Valueline/DataHero compilation of DART statements, accessed 16 Oct 2026
Income Statement
Notes:
-
FY2022 revenue growth is derived from FY2021 398.7 and derived FY2022 386.0.
-
FY2025 D&A = PPE depreciation 20.9 + intangible amortisation 1.3 (Valueline TTM to Dec-2025).
-
EPS = net income ÷ year-end share count on Valueline's stock-dividend-adjusted series (44.42 m for 2021 to 44.55 m for 2025).
-
Cash DPS: FY2023 and FY2024 dividends were stock-only.
Revenue CAGR FY2021–FY2025: 7.7%: (derived: (536.4 / 398.7)^(1/4) − 1).
FY2022–FY2025 CAGR: 11.6%: (derived).
Quarterly run-rate (KRW bn)
Sources: Q2 2026 fair-disclosure summary (StockHub, 4 Aug 2026) for Q2 2025–Q2 2026. Q1 2025 is derived from H1 2026 cumulative figures and their stated YoY growth rates (Dailian, 4 Aug 2026): revenue 285.4 (+17.1%), OP 32.2 (+22.7%), NI 22.5 (+22.4%). The four 2025 quarters reconcile to the FY2025 totals (536.4 / 56.0 / 38.8).
H1 2026 summary: revenue KRW 285.4 bn (+17.1%), operating income KRW 32.2 bn (+22.7%), net income KRW 22.5 bn (+22.4%). Trailing-twelve-month (TTM) to June 2026: revenue KRW 578.0 bn, operating income KRW 62.0 bn, net income KRW 42.9 bn (derived from quarterly sum).
Commentary — trends, inflections and drivers
FY2021 step-change: Revenue jumped 70.7% as the Takeda-origin portfolio (Nesina, Actos, Idalbi), worth ~KRW 70 bn in 9M 2021 alone, was layered onto Godex and the biosimilar trio. The trio rose ~18% to ~KRW 51.3 bn. Global chemical shipments also contributed.
FY2022–FY2023 plateau: Revenue stalled near KRW 386–389 bn. Operating income fell from KRW 47.8 bn to KRW 36.1 bn. The company cited endemic-phase normalisation and intensifying generic competition. In FY2023 R&D expense rose 58.9% to KRW 12.7 bn as the company built a modified-combination pipeline.
FY2024 volume inflection, margin trough: Revenue +22.9%, driven by PFS commercial production (+265% to KRW 92.6 bn), Dilatrend's first full year (KRW 50.2 bn) and chemicals (+23%). Operating margin, however, fell to 7.8%. Causes cited: generic price cuts decided in 2023, labour cost from pre-staffing new production capacity, and higher R&D. Q2 2024 OP fell 36.1% YoY on a 17.5% rise in cost of sales.
FY2025 operating leverage: Revenue +12.3%, but operating income +50.7% and net income +76.4%. Drivers: biosimilar revenue +50.8% (new launches), maximum PFS utilisation, and cost-of-goods relief from in-sourced Takeda brands, plus lower commission costs.
2026 trajectory: H1 2026 OP growth (+22.7%) outpaced revenue (+17.1%). Q2 2026 delivered a record OP of KRW 19.3 bn at a 12.6% margin, driven by CMO (+53.4%). IBK forecasts FY2026 operating income growth of ~25.5%, which implies ~KRW 70 bn on the FY2025 base (derived).
Balance Sheet
Latest interim (30 June 2026):
-
Total assets KRW 779.2 bn; equity KRW 449.2 bn; total liabilities KRW 330.0 bn
-
Cash KRW 51.7 bn; short-term financial instruments KRW 72.1 bn
-
Short-term borrowings KRW 142.0 bn; no long-term bank borrowings
-
Net debt ~KRW 18.2 bn (derived)
-
Intangibles rose to KRW 60.8 bn (software and other intangibles up; 2025 intangible additions of KRW 12.7 bn TTM to Mar-2026)
-
Book value per share KRW 10,116
Commentary:
Deleveraging: The balance sheet has steadily de-levered. Net debt fell from KRW 121.0 bn (FY2023) to KRW 25.0 bn (FY2025), as long-term bank loans were fully repaid and cash plus short-term deposits rose to KRW 117.0 bn.
Short-term funding: All remaining borrowings are short-term revolving facilities (KRW 142.0 bn). Refinancing reliance is therefore concentrated in a 12-month window, though this is typical of Korean mid-cap pharma working-capital lines.
Working capital: Working capital expanded as inventories grew (KRW 69.2 bn → KRW 122.9 bn, FY2022–FY2025), reflecting new biosimilar SKUs and in-sourced manufacturing. Receivables are structurally high, which is normal for Korean hospital channels.
Capacity plan vs balance sheet: The announced KRW 2 trn PFS plan dwarfs the current asset base (KRW 779 bn) and cash (~KRW 124 bn incl. ST deposits at Jun-2026). Dailian (2 Jul 2026) highlighted this mismatch. A company official characterised the figure as a scale under review rather than a finalised project.
Cash Flow
FY2025 values are trailing-twelve-month to 31 Dec 2025 per Valueline/DART.
TTM to 30 June 2026: OCF KRW 61.9 bn; PP&E capex KRW 12.2 bn; FCF (OCF − capex) KRW 49.7 bn; cash dividends paid KRW 8.7 bn (the first FY2025 cash dividend); treasury share purchases KRW 2.2 bn. The decline in TTM OCF versus FY2025 reflects working-capital absorption: receivables +KRW 14.1 bn, inventory +KRW 12.1 bn and prepayments +KRW 9.1 bn on a TTM basis.
Ratios
Notes:
-
ROIC: NOPAT = OP × (1 − 22% effective tax rate, derived from FY2025 tax ÷ pre-tax).
-
Market data (Valueline, 15 Oct 2026, TTM basis): ROE 9.55%, P/E 37.85x, P/B 3.61x.
Ratio commentary. Returns troughed in FY2023–FY2024, with ROE around 5.7–5.8%, as revenue growth was absorbed by generic price cuts, staffing ahead of capacity, and R&D. FY2025 marks a clear inflection: ROE 9.3%, ROA 5.4%, interest cover 8.4x. That inflection is driven almost entirely by the CMO and biosimilar legs. Receivable days are improving (208 → 150) as the CMO mix, billed to Celltrion, rises. Leverage is low, and the company is effectively net-cash-neutral after short-term deposits.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Revenue by Segment (%)
| Segment (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Chemical pharmaceuticals (as disclosed) | 166.5 | 204.8 | 214.0 |
Biosimilars (as disclosed) | 73.3 | 86.6 | 130.6 |
CMO total (FY2024 derived from FY2025 +2.8%) | — | 135.8 | 139.6 |
of which PFS commercial production | 25.4 | 92.6 | — |
Residual / not itemised (derived) | — | 50.6 | 52.2 |
Total revenue | 388.8 | 477.8 | 536.4 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2024 | FY2025 |
|---|---|---|
Chemical revenue growth YoY | 23.0 | 4.5 |
Biosimilar revenue growth YoY | 18.2 | 50.8 |
CMO revenue growth YoY | — | 2.8 |
PFS commercial production growth YoY | 265.0 | — |
Chemical share of total revenue | 42.9 | 39.9 |
Biosimilar share of total revenue | 18.1 | 24.3 |
CMO share of total revenue | 28.4 | 26.0 |
Revenue by Segment
| Segment (KRW Bn) | Q2 2025 | Q2 2026 | YoY % |
|---|---|---|---|
Chemical | 66.3 | 67.0 | 1.1 |
Biosimilar / Bio | 32.5 | 36.6 | 12.5 |
CMO | 32.4 | 49.7 | 53.4 |
of which PFS commercial production | 23.2 | 35.3 | 51.9 |
Total | 131.3 | 153.3 | 16.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 398.7 | 386.0 | 388.8 | 477.8 | 536.4 |
Revenue growth YoY (%) | 70.7 | -3.2 | 0.7 | 22.9 | 12.3 |
Operating income (KRW Bn) | 47.8 | 38.2 | 36.1 | 37.2 | 56.1 |
Operating income growth YoY (%) | 102.3 | -20.1 | -5.5 | 3.1 | 50.7 |
D&A (KRW Bn) | — | — | — | — | 22.2 |
EBITDA (KRW Bn, derived = OP + D&A) | — | — | — | — | 78.3 |
Pre-tax income (KRW Bn, derived = NI + tax) | — | — | — | — | 49.8 |
Income tax expense (KRW Bn) | — | — | — | — | 11.0 |
Net income (KRW Bn) | 34.6 | 26.0 | 21.3 | 21.9 | 38.8 |
EPS basic (KRW, derived on adjusted shares) | 779 | 584 | 478 | 492 | 871 |
Cash dividend per share (KRW) | — | — | 0 | 0 | 200 |
Operating margin (%) | 12.0 | 9.9 | 9.3 | 7.8 | 10.5 |
EBITDA margin (%) | — | — | — | — | 14.6 |
Net margin (%) | 8.7 | 6.7 | 5.5 | 4.6 | 7.2 |
R&D expense (KRW Bn) | — | 8.0 | 12.7 | — | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 112.4 | 131.3 | 138.2 | 154.4 | 132.1 | 153.3 |
Operating income (KRW Bn) | 10.7 | 15.5 | 16.1 | 13.7 | 12.9 | 19.3 |
Net income (KRW Bn) | 7.3 | 11.1 | 11.5 | 8.9 | 8.8 | 13.7 |
Operating margin (%) | 9.5 | 11.8 | 11.6 | 8.9 | 9.8 | 12.6 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW Bn) | 599.7 | 641.6 | 669.5 | 759.4 |
Current assets (KRW Bn) | 311.9 | 364.8 | 391.7 | 470.6 |
Cash & equivalents (KRW Bn) | 31.4 | 19.7 | 45.5 | 49.9 |
Short-term financial instruments (KRW Bn) | 17.7 | 17.4 | 24.1 | 67.1 |
Trade receivables (KRW Bn) | 185.8 | 222.1 | 212.9 | 220.3 |
Inventories (KRW Bn) | 69.2 | 100.4 | 101.4 | 122.9 |
Property, plant & equipment (KRW Bn) | 227.8 | 216.4 | 205.6 | 201.6 |
Goodwill (KRW Bn) | 32.9 | 32.9 | 32.9 | 32.9 |
Goodwill & intangibles total (KRW Bn) | 41.3 | 39.3 | 39.2 | 43.2 |
Short-term borrowings (KRW Bn) | 121.2 | 136.5 | 150.6 | 142.0 |
Current portion of long-term borrowings (KRW Bn) | 17.3 | 17.3 | 4.3 | 0 |
Long-term borrowings (KRW Bn) | 21.7 | 4.3 | 0 | 0 |
Total borrowings (KRW Bn) | 160.2 | 158.1 | 154.9 | 142.0 |
Net debt (KRW Bn, borrowings − cash − ST financial) | 111.1 | 121.0 | 85.3 | 25.0 |
Current liabilities (KRW Bn) | 212.0 | 249.3 | 247.7 | 283.6 |
Total liabilities (KRW Bn) | 242.9 | 265.0 | 272.5 | 323.5 |
Shareholders' equity (KRW Bn) | 356.8 | 376.7 | 396.9 | 436.0 |
Working capital (KRW Bn, CA − CL) | 99.9 | 115.4 | 144.2 | 187.0 |
Cash Flow
| Metric | FY2025 |
|---|---|
Operating cash flow (KRW Bn) | 86.4 |
Capex — PP&E (KRW Bn) | 16.2 |
Capex — intangibles (KRW Bn) | 1.8 |
Free cash flow (KRW Bn, OCF − PP&E capex) | 70.2 |
Dividends paid in cash (KRW Bn) | 0 |
Treasury share purchases (KRW Bn) | 2.4 |
Interest expense (KRW Bn) | 6.7 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE (%, NI ÷ average equity) | 7.3 | 5.8 | 5.7 | 9.3 |
ROA (%, NI ÷ average assets) | — | 3.4 | 3.3 | 5.4 |
ROIC (%, NOPAT ÷ (equity + net debt), derived) | — | — | — | 9.5 |
Current ratio (x) | 1.47 | 1.46 | 1.58 | 1.66 |
Debt / equity (x, borrowings ÷ equity) | 0.45 | 0.42 | 0.39 | 0.33 |
Net debt / EBITDA (x) | — | — | — | 0.32 |
Interest coverage (x, OP ÷ interest expense) | — | — | — | 8.4 |
Asset turnover (x) | — | 0.63 | 0.73 | 0.75 |
Days sales outstanding (days, year-end receivables) | — | 208 | 163 | 150 |
Revenue by Region
| Channel (KRW Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Domestic chemical + domestic biosimilar (disclosed segments) | 239.8 | 291.4 | 344.6 |
CMO, predominantly related-party to Celltrion, end-use mostly ex-Korea | — | 135.8 | 139.6 |
Residual / not itemised (may include exports) | — | 50.6 | 52.2 |
Total revenue | 388.8 | 477.8 | 536.4 |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Share price, year-end (KRW, adjusted) | 59,621 | 86,170 | 55,601 | 58,000 |
Market capitalisation, year-end (KRW Bn) | 2,647.9 | 3,833.9 | 2,476.3 | 2,583.9 |
Price / book, year-end (x) | — | 10.18 | 6.24 | 5.93 |
Shares outstanding (m, adjusted series) | 44.49 | 44.52 | 44.54 | 44.55 |
Valuation Multiples
| Multiple | Celltrion Pharm | Celltrion, Inc. (reference) |
|---|---|---|
P/E (x) | 37.8 | 34.4 (FY2026F, Kiwoom, Jan 2026) |
EV/EBITDA (x) | ~19.3 | 21.9 (FY2026F, Kiwoom) |
EV/Sales (x) | ~2.8 | — |
P/B (x) | 3.61 | 2.10 (FY2026F, Kiwoom) |
Dividend History
| Fiscal year | Cash DPS (KRW) | Stock dividend (shares per share) | Notes |
|---|---|---|---|
FY2023 | 0 | 0.05 | 1,972,158 new shares |
FY2024 | 0 | ~0.05 | ~2.06 m new shares; one source prints 0.005 (discrepancy) |
FY2025 | 200 | 0.02 | ~KRW 8.7 bn cash paid in 2026; ~43.42 m eligible shares |
Analyst Conclusions
Management guidance. No numeric guidance for Celltrion Pharm. Management targets continued "high growth" with a profitability focus in 2026. It plans to maximise PFS utilisation, expand new-biosimilar prescriptions and improve chemical margins via in-sourcing.
Consensus expectations. Only IBK's published forecast was identified: FY2026 OP growth of ~25.5%, implying ~KRW 70 bn on the FY2025 base (derived). The H1 2026 run-rate (OP KRW 32.2 bn, +22.7%) is consistent with this. A seasonally stronger H2 is expected, given the parent's H2-weighted tender season and Q3 2026 strength.
Bull case
-
CMO volume leverage. PFS commercial production grew 51.9% in Q2 2026. The parent's Q3 2026 preliminary revenue rose 45.8%, and its SC products (Zymfentra, Yuflyma, Omlyclo, Steqeyma) are gaining US and EU share. High-margin fill-finish volumes should keep compounding.
-
Domestic biosimilar breadth. The portfolio moves from 3 legacy products to 11+ (and 18 by 2030). FY2025 biosimilar revenue rose 50.8%, and Omlyclo and Vegzelma are growing 90–200% YoY.
-
Balance-sheet capacity and re-rating potential. Net debt is ~KRW 18 bn and ROE has inflected to ~9.5%. The stock is down 37% YTD while earnings hit records, which may compress the historic premium toward fundamentals. IBK's target implies ~67% upside.
Bear case
-
Concentration and transfer-pricing risk. ~88% of CMO revenue and all biosimilar supply depend on Celltrion. The parent's own Songdo and Yesan DP build-out could divert future fill-finish volumes.
-
Capex overreach. A ~KRW 2 trn plan against ~KRW 124 bn of liquid assets implies heavy external funding (equity, debt or parent support) and execution risk. Benefits arrive no earlier than 2032.
-
Structural valuation overhang. P/E of ~38x and P/B of 3.6x remain above the parent. Group-structure uncertainty persists after the 2024 merger rejection. Generic price cuts cap chemical growth (Q2 2026 chemical +1.1%).
Key catalysts and monitorables (next 12 months)
-
Q3 2026 results (~mid-Nov 2026): CMO growth sustainability and OPM vs the Q2 record of 12.6%
-
Q4 2026 / FY2026 results (~Feb 2027): confirmation of ~25% OP growth
-
Definitive PFS investment decision: site, phasing, funding structure and any parent participation
-
Any external (non-Celltrion) CMO contract announcement
-
Korean launches of Herzuma SC and CT-P55 (secukinumab); new-biosimilar prescription ramps
-
FY2026 dividend decision (Dec 2026): continuation of the cash component
-
Generic price-policy changes and reimbursement re-evaluations
-
Any signal on revisiting a Celltrion–Pharm combination (currently none; treat as speculative)
Concluding analyst verdict
Celltrion Pharm has completed a quiet but decisive transformation. It is no longer primarily a Korean generics house. As of H1 2026, more than half of revenue comes from distributing its parent's biosimilars and filling its parent's prefilled syringes. The financial consequences are now visible. FY2025 operating profit rose 50.7% to KRW 56.1 bn, Q2 2026 set a record at KRW 19.3 bn, ROE has recovered to ~9.5%, and net debt has fallen close to zero. These gains rest on durable drivers: the parent's accelerating SC franchise in the US and Europe, and a policy environment in Korea that favours biosimilar adoption.
The investment debate is not about growth, but about who captures it. Celltrion Pharm's profitability is set within a related-party system. Celltrion supplies the products, buys the CMO output, and is simultaneously building its own drug-product capacity. The 2024 merger collapse showed that parent-company shareholders view Pharm's valuation sceptically, and the market has since de-rated the stock by more than a third in 2026 even as earnings hit records. At ~38x TTM earnings and 3.6x book, the shares are no longer extreme relative to the parent. They still embed confidence that intra-group economics will remain favourable and that the ~KRW 2 trn PFS expansion will be funded and filled.
On balance, the operating trajectory is clearly positive and the near-term earnings set-up favourable: H2 seasonality plus strong parent Q3 volumes. But governance and concentration risks are structural, not cyclical. Investors should treat Celltrion Pharm as a higher-beta, lower-control proxy for Celltrion's SC strategy. It is attractive on momentum and balance-sheet strength. Its re-rating, however, depends on concrete evidence of external CMO diversification, a credible financing plan for the capacity programme, and fuller segment disclosure that reconciles revenue and reveals segment margins. Until then, a balanced-to-constructive stance, sized for event risk around group restructuring and capex decisions, appears warranted.
-
parent ownership: 54.81% vs 54.99% vs 53.81%
-
FY2024 stock dividend ratio: 0.005 vs ~0.05 implied
-
founding/establishment date: 1976 vs 2000 vs 2009
-
annual segment totals vs reported revenue
Derived figures are labelled with their method. None were estimated.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Background | Compensation |
|---|---|---|---|---|
Yoo Young-ho (유영호) | President & CEO | CEO since Jan 2024 | Previously executive vice president (부사장) within the Celltrion group; promoted to president with the CEO appointment (Kormedi, 2 Jan 2024). Leads the PFS investment programme. | Not publicly disclosed in sources reviewed. Korean rules require disclosure only for executives paid ≥KRW 500 m. |
Seo Jung-jin (서정진) | Inside director and co-chairman of the board (appointed 28 Mar 2023, 2-year term); Celltrion Group chairman | Group founder | Founder of Celltrion. Returned to boards of all listed group companies in March 2023. Re-elected at Celltrion, Inc. in March 2025. | Not disclosed for Celltrion Pharm |
Seo Jung-soo (서정수) | Former CEO (2016–2023); now Celltrion vice chairman | CEO ~8 years | Inha University (accounting); ex-GS E&C executive; joined Celltrion 2012; Celltrion president 2014 | — |
Major Shareholders
| Holder | Stake | Source / date |
|---|---|---|
Celltrion, Inc. | 54.81%–54.99% | Korea Times (Aug 2024), sell-side notes (2024–2026); Dailian (Jul 2026) |
Treasury shares | ~0.26 m shares (~0.6%) | Dividend notice, Dec 2025 |
Free float / minority investors | ~44–45% (derived) | — |
Competitive Landscape
Peer Comparison FY2025
| Company (FY2025) | Revenue (KRW Bn) | Revenue growth (%) | Operating margin (%) |
|---|---|---|---|
Celltrion Pharm | 536.4 | 12.3 | 10.5 |
Chong Kun Dang | 1,692.4 | 6.7 | 4.8 |
Daewoong Pharmaceutical | 1,570.9 | — | 12.5 |
Hanmi Pharmaceutical | 1,547.5 | — | 16.7 |
Recent Developments
Celltrion Pharm's Q3 2026 results had not been released as of the research cut-off. Historically they arrive in mid-November.



